Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Finance: Asset renaissance

How Medicxi increases Phase II successes with less capital

By Steve Edelson, Senior Editor

The former life sciences team from Index Ventures has set up shop as Medicxi Ventures with a heavily oversubscribed new fund, and an investment model that has so far scored it a 100% success rate in Phase II readouts while halving the capital needed to get there.

Medicxi is taking with it the 12-person life sciences team from Index, the remaining capital from the almost fully invested Index Ventures Life VI fund, and a portfolio of about 40 life sciences companies.

Read Article
  • THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.

    This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.

    This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.